Last reviewed · How we verify
CXA-201
CXA-201 is a novel antibiotic that inhibits bacterial protein synthesis by targeting the ribosome.
CXA-201 is a novel antibiotic that inhibits bacterial protein synthesis by targeting the ribosome. Used for Complicated urinary tract infections (cUTI), Acute bacterial cystitis, Gram-negative bacterial infections.
At a glance
| Generic name | CXA-201 |
|---|---|
| Sponsor | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
| Drug class | Fluoroquinolone antibiotic |
| Target | Bacterial DNA gyrase and topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
CXA-201 is a fluoroquinolone-class antibiotic developed to treat serious gram-negative bacterial infections. It works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication and cell division, thereby preventing bacterial growth and survival.
Approved indications
- Complicated urinary tract infections (cUTI)
- Acute bacterial cystitis
- Gram-negative bacterial infections
Common side effects
- Nausea
- Diarrhea
- Headache
- Tendinopathy
Key clinical trials
- Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections (PHASE3)
- Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: